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Drug resistance against gemcitabine and topotecan mediated by constitutive
hsp7O overexpression in vitro: implication of quercetin as sensitiser in
chemotherapy
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'Department ofGynaecology and Obstetrics, University of Vienna, Medical School, 1090 Vienna, Austria; 2Centre ofApplied
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Summary Heat shock proteins have been reported to confer resistance to certain antineoplastic drugs. We
investigated the impact of hsp7o overexpression on the efficacy of two new anti-cancer drugs, topotecan and
gemcitabine. We used the fibrosarcoma WEHI-S cells stably transfected to overexpress the hsp70 cDNA from
the constitutive SV40 promoter and appropriate control cells. After topotecan and gemcitabine treatment
hsp70-overexpressing cells showed a marked elevation in cell survival, suggesting that hsp7o overexpression was
sufficient to confer resistance to the drugs. In addition, hsp70-overexpressing cells were capable of starting cell
proliferation after treatment with drug dosages that were lethal to control cells. Our results demonstrate that
hsp7o overexpression represents a possible cause of drug resistance. In order to transfer these data to tumour
cells constitutively expressing stress hsp70 due to the constitutive activity of the original hsp70 promoter we
sought to supress the heat shock response pathway by the natural flavonoid quercetin, known to inactivate the
heat shock transcription factor (HSF). Using a suitable cell line, we demonstrated the sensitising activity of
quercetin. We found that antineoplastic drug concentrations exerting cytotoxic activity were markedly lower
when cells were pretreated with quercetin. Concomitantly, hsp70 expression was strongly down-regulated under
quercetin treatment. Our data indicate that quercetin may be useful as a sensitiser in chemotherapeutically
treated patients suffering from hsp70-overexpressing tumours.
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Adverse changes in the environment of cells induce the
expression of heat shock proteins such as the 7OkDa heat
shock protein hsp70 (Lindquist and Craig, 1988). This
response takes place when cells are subjected to a wide
variety of stressors, e.g. environmental assaults or states of
disease (Parsell and Lindquist, 1994). The understanding of
stress response is still incomplete but the promise of its
clinical application and its role in cancer development is
under intense investigation. Hsp7O overexpression has been
reported to induce cytoprotection under a broad variety of
adverse conditions in vivo and in vitro (reviewed in Parsell
and Lindquist, 1994).
Antineoplastic drugs act via a variety of mechanisms,
including inhibition of topoisomerases or modification of
proteins and DNA. It has been reported that the over-
expression of certain heat shock proteins confers resistance to
at least some antineoplastic drugs (Osterreich et al., 1993;
Karlseder et al., 1996), therefore heat shock protein over-
expression in malignant cells could adversely influence the
efficacy of antineoplastic therapy (Ciocca et al., 1993; Fuqua
et al., 1994a,b). In the present study we used two new drugs,
topotecan [(S)-9-dimethylaminomethyl-10-hydroxycampothe-
cin hydrochloride; SK&F 104864-A, NSC 609699] and
gemcitabine, dFdC, (2',2'-difluorodeoxycytidine). Topotecan
is a water-soluble semisynthetic analogue of the alkaloid
campothecin, which is a potent topoisomerase I inhibitor.
Gemcitabine is a deoxycytidine antimetabolite, presumably
exerting its antineoplastic activity by the incorporation of
dFdC into the genome.
It was the purpose of this study to elucidate the influence
of hsp70 overexpression on the cytotoxic effects of topotecan
and gemcitabine using a fibrosarcoma WEHI-S cell line,
stably transfected to constitutively overexpress the human
hsp70 (Hunt and Morimoto, 1985) cDNA (WN113) and a
corresponding control transfected with an empty plasmid
(Jaiattela et al., 1992).
Hsp7O overexpression has been reported in several human
malignancies. In contrast to the artificial overexpression of
hsp70 by the heterologous SV40 promoter in WN113 cells
these malignant cells express hsp70 obviously by constitutive
activation of their genuine hsp70 promoter. Given the
desensitising activity of hsp70 with respect to antineoplastic
therapy we sought to inactivate the transcriptional activity of
that promoter, thus sensitising these cells to topotecan and
gemcitabine. Inducible heat shock proteins, e.g. hsp90, hsp70
or hsp27, are transcriptionally regulated by heat shock
transcription factors (HSFs) (Larson et al., 1988). HSF is
expressed constitutively in an inactive form and post-
translationally activated by a variety of events. The
transcriptionally active HSF molecule migrates into the
nucleus and binds to a promoter element (HSE), which
most stress-inducible promoters of heat shock protein genes
have in common. Upon HSF binding to HSE the promoter is
transcriptionally active and the heat shock proteins con-
trolled by this mechanism are expressed (for review see
Morimoto et al., 1994). Cells constitutively bearing an
activated HSF consequently not only express hsp27 but also
other protective heat shock proteins, e.g. hsp90 or hsp27, all
of which are regulated by this factor (Parsell and Lindquist,
1994). In order to sensitise hsp-overexpressing tumour cells
quercetin (3, 3', 4', 5, 7-pentahydroxyflavone), a bioflavonoid,
which is found as a glycoside in citrus fruits, is a promising
candidate molecule, as it has been reported to suppress the
stress response in heat-shocked cells (Nagai et al., 1995; Lee
et al., 1994). Therefore, we applied quercetin as a sensitiser
molecule to suppress hsp70 overexpression. To test the
sensitising efficiency of quercetin in vitro, we used HaCaT
cells (Boukamp et al., 1990; Breitkreutz et al., 1991), which
naturally show constitutive overexpression of hsp70.
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Materials and methods
Cell culture
To study the efficacy of high expression levels ofhsp70 on the
sensitivity to anti-cancer drugs an isogenic set of stably
transfected murine fibrosarcoma cell lines, kindly donated by
Dr Marja Jaiittela, Danish Cancer Society Research Centre,
Copenhagen, Denmark, was used (Jaiittela et al., 1992).
WN113 cells were generated by transfection of WEHI-S cells
with a SV40-driven human hsp7O cDNA expression vector.
WN1Ox cells represent a mixed culture of WEHI-S clones
stably transfected with an empty control plasmid. Both
WNl 13 and WN1Ox cells were co-transfected with a vector
carrying the neomycin resistance gene for adequate selection
by use of G418. Cells were propagated in RPMI-1640 culture
medium, containing 10% fetal bovine serum, 2 mM
glutamine, 1% antibiotic/antimycotic supplements and
200 ,ug ml-' G418 (all Gibco, UK). Monolayer cells were
routinely passaged at subconfluence by 0.25% trypsin-EDTA.
To avoid an induction of the heat shock response media and
phosphate buffered saline (PBS) were equilibrated at 37°C
before use.
The human skin keratinocyte cell line (HaCaT) was
provided by Professor Dr N E Fusenig, Institute of
Biochemistry, German Cancer Research Centre, Heidelberg,
Germany. HaCaT cells served as an example for tumour cells
that show enhanced hsp7o expression levels. They were
routinely grown in RPMI-1640 medium, containing 10%
fetal bovine serum, 2 mM glutamine, 1% antibiotic/antimy-
cotic supplement.
Chemotherapeutic drugs and cytotoxicity assay
Topotecan [(S)-9-dimethylaminomethyl-10-hydroxycampoth-
ecin hydrochloride; SK&F 104864-A, NSC 609699] was
kindly provided by SmithKline Beecham Pharma, UK. This
drug was shown to be active in a lactone form only (Burke
and Mi, 1994). The equilibrium of lactone and carboxylate
form is dependent on pH, protein concentration and other
factors. The actual concentration of lactone for this in vitro
model was not determined, therefore, the concentrations
used in our in vitro conditions, which were stable whithin
the experiments, cannot be compared with those applied in
vivo. Gemcitabine (2',2'-difluorodeoxycytidine) was a gift
from Eli Lilly, Austria. The antineoplastic drugs were
dissolved in dimethyl sulphoxide (DMSO) and stored as
recommended. Growth inhibition was determined essentially
as described previously (Simon et al., 1995). Briefly, 100,l
of cell suspension was seeded at a density of 5 x 104 cells
ml-' in 96-well plates in RPMI-1640 culture medium,
containing 10% fetal bovine serum and 200 Mg ml-' G418
(all from Gibco). After 16 h medium was replaced and cells
were incubated with the antineoplastic drugs at concentra-
tions as indicated. A negative control sample was prepared
by complete lysis of cells by addition of 5% of sodium-N-
lauroylsarcosin (Sigma, St Louis, MO, USA). As the
doubling rates of WN1Ox and WN113 cells were found to
be essentially the same (data not shown) actual cell numbers
were not determined at the time point of drug addition.
Cells were exposed to the antineoplastic drugs for a period
of 48 h at 37°C. To determine the metabolic activity 20 ,l of
MTT solution (Sigma 1.5 mg ml-') dissolved in RPMI-1640
was added and incubated at 37°C for exactly 6 h. Then
100 Ml of lysis buffer [10% sodium dodecyl sulphate (SDS),
50% formamide adjusted to pH 4.7 with acetic acid] was
added and incubated overnight at room temperature to lyse
cells and solve the formazane precipitate. The clear solution
was measured at 595 nm on a baseline of the completely
lysed negative control extinction. The resulting percentage
growth inhibition rates represent the metabolic activity
(OD595) after a 48 h period of culture in continuous
presence of the drugs. All experimental series were
performed independently at least three times and minimally
in triplicates.
Determination of the ability of cells to re-enter the cell cycle
after drug withdrawal
To determine the capability of cells to restart cell growth
after withdrawal of the drugs two identical sets of 96-well
plates were seeded and treated with the drugs as described.
After a period of 24 h the metabolic activity was determined
in the first set of 96-well plates whereas the second set was
washed twice and grown for an additional 48 h. The
metabolic activity was then also determined in the second
set. The capability of cells to restart cell growth was
expressed as the percentage increase (or decrease) of OD595
of the second set containing recovered cells compared with
the OD595 measured at the time point of removal ofthe drug
(set to 100%). A change in metabolic activity exceeding
100% indicates that cells were able to re-enter the cell cycle
after withdrawal of the drug, whereas values below 100%
demonstrated that cells were still arrested or had died.
Quercetin treatment
The sensitising effect of quercetin was assayed in HaCaT
cells, which show constitutive hsp70 expression. A quercetin
stock solution was prepared in DMSO. Sterile filtered
aliquots were kept at -20°C. The toxicity of quercetin was
determined by an MTT assay as described for the drugs after
continuous treatment for 48 h. As high doses of quercetin
interfered with the MTT colour reaction, cells were washed
before the addition of the MTT assay medium. In order to
inactivate the constitutively active heat shock transcription
factor in HaCaT cells they were grown for 36 h in the
presence ofquercetin at concentrations as indicated. After the
medium containing the same quercetin concentration was
changed the drugs were added followed by an incubation for
48 h. Then a growth inhibition assay was performed as
described. The cell survival is expressed as per cent OD595 of
treated cells vs non-treated cells normalised to the completely
lysed negative control.
Western blot analysis.
HaCaT cells were propagated as mentioned, supplemented
with 10% fetal calf serum (FCS) in the presence of indicated
concentrations of quercetin for 36 h. Cells were detatched
from the culture plates by use of a rubber policeman.
Cytosolic protein lysates were essentially prepared as
described previously (Simon et al., 1994). Briefly, cells were
allowed to swell in hypotonic buffer [10 mM HEPES, pH 7.8,
0.1 mM ethylenediamine tetraacetic acid (EDTA), 10 mM
KCl, potassium chloride 1 mM dithiothreitol (DTT), phenyl-
methylsulphonyl fluoride (PMSF)] for 15 min on ice. Equal
amounts of protein as determined using the ProteinAssay
(Biorad, Vienna, Austria) were subjected to denaturing SDS/
polyacrylamide electrophoresis and subsequently blotted onto
nitrocellulose filters. Hsp7O was detected by use of an
antibody specific for the stress-inducible hsp7o (anti-hsp72,
SPA810, StressGen Victoria, BC, Canada) and an alkaline
phosphatase coupled anti-mouse IgG antibody (Boehringer
Mannheim, Mannheim, Germany).
Results
Hsp7O overexpression is sufficient to render cells resistant to
topotecan and gemcitabine
The cytotoxic activity of topotecan and gemcitabine for
control WN1Ox and WNI113 cells was determined. WN113
cells are stably transfected to express high levels of hsp7o
using the constitutive viral SV40 promoter. Figure 1
demonstrates the impact of hsp7o on the drug sensitivity.
Whereas the protective effect against gemcitabine was
moderate with a factor of 2-3, cells overexpressing hsp7o
could bear an almost 10-fold topotecan dosage. The inhibitor
of topoisomerase I, topotecan, showed a relatively narrowSonsitisation to hsp70-mediated drug resistance
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Figure 1 Influence of hsp70 overexpression on cell survival after
treatment with topotecan or gemcitabine. WNl 13 and WNlOx
cells were seeded in 96-well plates and incubated overnight. Then
topotecan (a) or gemcitabine (b) was added at concentrations as
indicated. After 48h of incubation at 37°C an MTT assay was
performed. (WNlOx, *; WN113, 0). Values represent metabolic
activity remaining after 48 h continuous drug exposure compared
with the untreated control. Error bars represent standard
deviations. Assays were performed in quadruplicates.
concentration range where the metabolic activity dropped to
some 30%, whereas for the antimetabolite gemcitabine this
cytotoxic range was larger. Determination of metabolic
activity after a 72 h incubation period revealed similar
results. We conclude that hsp70 overexpression is sufficient
to render cells resistant to topotecan and gemcitabine.
Hsp70 overexpression desensitises cells to the growth-inhibiting
activity of topotecan and gemcitabine
The most important question with regard to cancer treatment
is not only if the tumour cells die or arrest their growth but
whether cells treated with anti-cancer drugs are capable of
restarting cell growth when the drug concentration drops to
non-effective doses. This is of particular interest, as the vast
majority of drugs bear a considerable genotoxic potential.
Therefore, we determined the capability of cells to restart cell
growth by comparing metabolic activity (OD595) of WN113
and WNIOx cells immediately after a 24 h period of drug
treatment with their metabolic activity after withdrawal of
the drugs and subsequent culture for 24 h. As depicted in
Figure 2, WN113 cells were capable of starting cell
proliferation at doses at which WNIOx cells were not able
to grow or showed decreased metabolic activities. The effect
was more pronounced regarding pretreatment with topote-
can. WNl 13 cells were able to restart cell growth having
Figure 2 Influence ofhsp70 on the start ofcell proliferation after
drug treatment. WNO0 x cells (_) and WN113 cells (LI) were
seeded into 96-well plates. After adherence they were treated with
topotecan (a) or gemcitabine (b) and incubated for 48h. After
48 h the drugs were removed by washing twice with medium and
metabolic activity was determined as described. Another set of 96-
well plates were treated by the same procedure but grown for an
additional 24h followed by a standardised MTT metabolic
activity assay. Assays were performed in quadruplicate. Given
values represent the mean percentage of metabolic activity
contained in the wells after growth for a total of 72h (48 h in
the presence of the drug and 24h without the drug) compared
with the metabolic activity after 48h. The metabolic activity
assayed at the 48h time point was taken as 100%. Error bars
represent the corresponding standard deviation.
faced 90 ng ml-' topotecan, whereas WN1Ox cells were not
able to restart growth after treatment with a two orders of
magnitude lower dosage. The maximally tolerable dose of
gemcitabine allowing the restart of growth was only 2 to 3-
fold higher when hsp70 was overexpressed. Taken together,
these results suggest that hsp7O overexpression provides not
only a transient cytoprotection to topotecan and gemcitabine
but also enables protected cells to proliferate after treatment
of enhanced drug doses.
Quercetin sensitises constitutively hsp7O-overexpressing cells to
topotecan and gemcitabine
Tumour cells constitutively overexpressing heat shock
proteins have been documented during recent years (Ciocca
et al., 1993; Fuqua et al., 1994a,b). Heat shock proteins such
as hsp70 or hsp27 were therefore considered for application
as tumour markers. In view of our results, that over-
expression of hsp70 provides drug resistance, we sought to
lower the intracellular hsp7O level of such cells, thereby
sensitising them to chemotherapy. An epidermoid cell line,
HaCaT, which was found to constitutively express hsp70
from its genuine promoter was used as an example for
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Quercetin was demonstrated to disrupt the heat shock
response by inactivating the heat shock transcription factor.
Figure 3 shows a toxicity assay of quercetin on HaCaT cells.
A dose of 50 pM was not able to alter cell survival. A dose of
80 pM of quercetin caused a decrease of viability by 20%.
HaCaT cells have been cultured in the presence of up to
50 pM for more than 4 days without significantly altering
their doubling time as compared with untreated cells (data
not shown). For sensitisation HaCaT cells were pretreated for
a period of 36 h with quercetin to allow a decrease in the
hsp70 level. Shorter pretreatment or concomitant adminis-
tration of quercetin and the drugs were not effective (not
shown). As shown in Figure 4 the hsp70 level markedly
decreased in this period of time in a dose-dependent manner
as measured by Western blot analysis (control, untreated;
lane 1. 10 pM; lane 2. 30 pM and lane 3, 50 pM of quercetin).
A dose of 10 pM reduced the hsp70 level to approximately
50% compared with the untreated control, upon 50 pM hsp70
drops to the detection limit. as determined by densitometry
(data not shown). In order to evaluate the sensitisation
efficacy by quercetin. cells were preincubated for 36 h with
quercetin, medium was replaced containing fresh quercetin
and cells were then treated with the drugs. After 48 h of
incubation a cytotoxicity assay was performed. Note, that the
overall sensitivity of HaCaT cells was different from that of
the WNlOx cells, which were particularly sensitive to the
drugs used. As depicted in Figure 5 quercetin pretreatment
markedly increased the sensitivity of HaCaT cells to both
drugs in a concentration-dependent manner.
Discussion
The development of resistance of tumour cells to anti-cancer
drugs is one of the critical issues for successful chemotherapy.
Stress-inducible heat shock proteins render cells resistant to a
variety of antineoplastic drugs (Hahn and Li, 1990). In the
present study high levels of hsp7O induced by an expression
vector carrying the hsp70 cDNA transcribed from the strong
and constitutive SV40 promoter were sufficient to provide
protection against topotecan and gemcitabine in the isogenic
cell system of WNI13 and WNlOx cells. In order to draw
clinically relevant conclusions from our in vitro system
antineoplastic drugs were applied in concentrations near the
Sensi- saton to hsp7O-meaWd rug resistnice
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Figure 4 Effect of quercetin pretreatment on intracellular hsp7O
levels. HaCaT cells were grown in the presence of quercetin.
Cytosolic protein extracts were then prepared. An equal amount
of protein was subjected to SDS polyacrylamide electrophoresis.
Proteins were blotted onto intro-cellulose filters and hsp7O was
probed using an antibody specific for the stress-inducible form of
hsp70 (hsp72). Signal detection was performed by use of an
alkaline phosphatase-conjugated secondary antibody and a
subsequent colour reaction. Control. untreated cells: lane 1.
1OpM: lane 2. 30M and lane 3. 50jiM of quercetin.
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Figure 3 Toxicity of quercetin for HaCaT cells. Cells were
seeded into 96-well plates and incubated until adherence. They
were then treated with varying doses of quercetin as indicated and
grown for 48h. followed by determination of the viability by an
MTT assay. Values represent percentage metabolic activity
remaining after 48h of quercetin treatment compared with
untreated cells. The assay was performed in quadruplicate. Error
bars represent the corresponding standard deviation.
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Fire 5 Sensitisation of HaCaT cells by quercetin. HaCaT cells
were grown in the presence of quercetin at 10pUM (0). 30pM (A)
and without quercetin (U) for 36h. The medium containing
quercetin was then changed. It later contained quercetin in
concentrations as mentioned above. Subsequently. the cells were
treated with topotecan (a) or gemcitabine (b) and grown for 48 h.
The cell survival was then determined by measurement of
metabolic activities by an MTT assay. The assay was performed
in quadruplicate. Error bars represent the corresponding standard
deviation.
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maximum tolerable dose. From our results we conclude that
the antineoplastic activity of topotecan and gemcitabine is
reduced in hsp70-overexpressing cells. An hsp70-mediated
elevation of resistance by a factor of 2 or 3. as demonstrated
in our study. could be detrimental for the success of
chemotherapy. Furthermore, it could be speculated that the
protective action of hsp7O exhibits a certain drug specificity.
The protective effect of hsp70 overexpression against
cytotoxicity was more pronounced for topotecan than for
gemcitabine. This could be explained by different mechanisms
by which these drugs exert toxicity (Figure 1). A suggested
model on the mechanism of hsp7O-mediated cytoprotection is
based on the ability of hsp7O to bind misfolded or aggregated
proteins. The energy-dependent dissociation of the substrate
peptide-hsp70 complex is thought to enable these peptides to
acquire a proper folding (Gething and Sambrook. 1992).
Hsp7O in Escherichia coli was able to restore enzyme activity
of damaged proteins (Skowyra et al.. 1990; Schroder et al..
1993). However, a detailed mechanism of such a versatile
cross-protection as provided by overexpression of hsp7O and
other heat shock proteins with regard to the drugs used is not
known.
We found that hsp7O-overexpressing cells not only survive
enhanced doses of topotecan or gemcitabine but were also
able to start proliferation after application of antineoplastic
drug doses at which control cells remained arrested or died. It
was reported that hsp7O overexpression conferred resistance
to ultraviolet light or reactive oxygen intermediates (Simon et
al.. 1995) but on the other hand enhanced the number of
surviving mutants as a result of the DNA-damaging
treatment (Suzuki and Watanabe. 1994). Accordingly. the
pronounced capability to restart cell growth after drug
treatment could lead to the enhanced outgrowth of mutated
cells when hsp70 is overexpressed. Hsp7O-protected tumour
cells bear a higher risk of developing viable mutants, which
could give rise to secondary tumours after treatment with a
genotoxic chemotherapy. High constitutive expression of
hsp70 was found in a variety of tumours. in particular in
breast cancer, where hsp70 is regarded as an adverse
prognostic marker (Fuqua et al.. 1994b: Ciocca et al.. 1993;
Elledge et al.. 1994). Topoisomerase I inhibitors such as
topotecan show significant activity against a broad range of
tumours and are not substrates for the multidrug resistance
P-170 glycoprotein and the multidrug resistance-associated
proteins (Sinha. 1994). Gemcitabine. a new cytidine analogue.
has shown impressive activity as a single agent against several
solid malignancies. demonstrating that in solid tumours
deoxycytidine kinase can be an important target for the
activation of antimetabolites (Ruiz van Haperen and Peters.
1994). In addition. gemcitabine has also been shown to be
active against multidrug-resistant human tumours xeno-
grafted into nude mice (Fujita et al.. 1994a.b). The capability
of hsp7O-overexpressing tumour cells to regrow after
treatment with antineoplastic drugs consequently could be
of considerable importance in the clinical setting.
After demonstrating that hsp7O overexpression alone is
sufficient to desensitise cells to the antineoplastic activity of
topotecan and gemcitabine it was our aim to evaluate how
tumour cells, which naturally overexpress hsp7O. could be
sensitised to a chemotherapy with topotecan and gemcita-
bine. Such tumour cells are reported; however. the reason for
the high hsp7O expression in these cells is unknown. To gain
a model for a tumour cell that constitutively expresses hsp7O
by use of its genuine hsp7O promoter we used the HaCaT cell
line, which we found to be suitable for this purpose.
Inducible heat shock proteins. e.g. hsp9O. hsp7O or hsp27.
are transcriptionally regulated by heat shock transcription
factors (HSFs) (Larson et al.. 1988). Cells having constitu-
tively activated HSF consequently not only express hsp7O but
also other protective heat shock proteins. e.g. hsp9O or hsp27.
all of which are regulated by this factor (Parsell and
Lindquist. 1994). The combined expression of several
protective heat shock proteins therefore might account for
the decreased sensitivity of HaCaT cells to the drugs when
compared with WNl 13 cells. One possible access to lower the
overall level of heat shock proteins is to specifically block the
transactivating potential of HSF. Such HSF-inhibiting
properties were found for the flavonoid quercetin (Hosoka-
wa et al.. 1992). Pretreatment of HaCaT cells with different
dosages of quercetin dramatically reduced the hsp7O level
(Figure 4). dosages which did not affect the growth properties
of the cells (Figure 3). Continuous long-term culture in the
presence of less than 1 pm quercetin was effective in
significantly reducing hsp7O (data not shown). Quercetin
obviously is an effective tool for reducing genuine hsp7O
levels. It is likely that other protective heat shock proteins
that are under transcriptional control of HSF are also
suppressed by quercetin treatment. As expected quercetin
depleted HaCaT cells from protective hsp7O (Figure 4) and
consequently these cells showed a profound quercetin dosage-
dependent sensitisation to topotecan as well as to gemcita-
bine. In summary, we conclude that quercetin could be
considered as a chemosensitiser in combination with
conventional chemotherapy.
Acknowledgements
We wish to acknowledge Dr J Gloessl for critically reading the
manuscript and Dr S Slobodinsky for fruitful discussions. The
work was supported by a grant from the Mayor of Vienna to Dr G
Sliutz.
References
BOUKAMP P. STANBRIDGE EJ. FOO DY. CERUTTI PA AND
FUSENIG NE. (1990). c-Ha-ras oncogene expression in immorta-
lized human keratinocytes (HaCaT) alters growth potential in vivo
but lacks correlation with malignancy. Cancer Res.. 50, 2840-
2847.
BREITKREUTZ D. BOUKAMP P. RYLE CM. STARK HJ. ROOP DR
AND FUSENIG NE. (1991). Epidermal morphogenesis and keratin
expression in c-Ha-ras-transfected tumorigenic clones of the
human HaCaT cell line. Cancer Res.. 51, 4402- 4409.
BURKE TG AND MI Z. (1994). The structural basis of camptothecin
interactions with human serum albumin: impact on drug stability.
J. Med. Chem.. 37, 40-46.
CIOCCA DR. CLARK GM. TAN-DON AK. FUQUA SA. WELCH WJ
AND MCGUIRE WL. (1993). Heat shock protein hsp7O in patients
with axillarv lymph node-negative breast cancer: prognostic
implications. J. Natl Cancer Inst.. 85, 570- 574.
ELLEDGE RM. CLARK GM. FUQUA SA. YU YY AND ALLRED DC.
(1994). p53 protein accumulation detected by five different
antibodies: relationship to prognosis and heat shock protein 70
in breast cancer. Cancer Res.. 54, 3752- 3757.
FUJITA F. FUJITA M AND SAKAMOTO Y. (1994a). [Acquired
resistance and cross-resistance of gemcitabine to cisplatin or
vindesine in human lung cancer xenografted in nude mice]. Gan
To Kagaku Rvoho. 21, 2749-2755.
FUJITA M. FUJITA F. INABA H AND TAGUCHI T. (1994b).
[Antitumor activitv of LY 188011. a new deoxycytidine analog.
against human cancers xenografted into nude mice]. Gan To
Kagaku Ryoho. 21, 517-523.
FUQUA SA. BENEDIX MG. KRIEG S. WENG CN. CHAMNESS GC
AND OESTERREICH S. (1994a). Constitutive overexpression of
the 27.000 dalton heat shock protein in late passage human breast
cancer cells. Breast Cancer Res. Treat.. 32, 177- 186.
FUQUA SA. OESTERREICH S. HILSENBECK SG. voN- HOFF DD.
ECKARDT J AND OSBORNE CK. (1994b). Heat shock proteins
and drug resistance. Breast Cancer Res. Treat.. 32, 67- 71.
GETHING MJ AND SAMBROOK J. (1992). Protein folding in the cell.
Nature. 355, 33-45.Senstisation to hsp7O-meiated dugr, n ance
G Siutz et al
177
HAHN G AND LI GC. (1990). Thermotolerance. thermoresistance
and thermosensitation. In Stress Protein in Biology and .Medicine
RI Morimoto. A Tissiere and C Georgopoulos (eds). Cold Spring
Harbour Laboratory Press: Cold Spring Harbour. NY.
HOSOKAWA N. HIRAYOSHI K. KUDO H. TAKECHI H. AOIKE A.
KAWAI K AND NAGATA K. (1992). Inhibition ofthe activation of
heat shock factor in vivo and in vitro by flavonoids. Mol. Cell.
Biol.. 12, 3490-3498.
HUNT C AND MORIMOTO RL. (1985). Conserved features of
eukaryotic hsp70 genes revealed by comparison with the
nucleotide sequence of human hsp70. Proc. Natl Acad. Sci.
USA. 82, 6455-6459.
JAATTELA M. WISSING D. BAUER PA AND LI GC. (1992). Major
heat shock protein hsp70 protects tumor cells from tumor necrosis
factor cytotoxicity. EMBO J. 11, 3507-3512.
KARLSEDER J. WISSING D. HOLZER G. OREL L. SLIUTTZ G. AUER H.
JAATTELA M AND SIMON MM. (1996). Hsp7O overexpression
mediates the escape ofa doxorubicin induced G, cell cycle arrest.
Biochem. Biophas. Res. Commun. (in press).
LARSON JS. SCHUETZ TJ AND KINGSTON RE. (1988). Activation in
vitro of sequence-specific DNA binding by a human regulatory
factor. Nature. 335, 372 -375.
LEE YJ. ERDOS G. HOU ZZ. KIM SH, KIM JH. CHO JM AND CORRY
PM. (1994). Mechanism of quercetin-induced suppression and
delay of heat shock gene expression and thermotolerance
development in HT-29 cells. Mol. Cell. Biochem.. 137, 141- 154.
LINDQUIST S AND CRAIG EA. (1988). The heat shock proteins.
Annu. Rev. Genet., 22, 631-677.
MORIMOTO RI. JURIVICH DA. KROEGER PE. MATHUR SK.
MURPHY SP. NAKAI A SARGE K. ABRAVAYA K AND SISTONEN
LT. (1994). Regulation of heat shock gene transcription by a
famiily of heat shock factors. In The Biology of Heat Shock
Proteins and Molecular Chaperones RI Morimoto. A Tissiere and
C Georgopoulos (eds) p. 417. Cold Spring Harbor Laboratory
Press: Cold Spring Harbor, NY.
NAGAI N. NAKAI A AND NAGATA K. (1995). Quercetin suppresses
heat shock response by down regulation of HSF1. Biochem.
Biophvs. Res. Commun.. 208, 1099- 1105.
OSTERREICH S. WENG C-N. QIU M. HILSENBECK SG. OSBORNE CK
AND FUQUA SAW. (1993). The small heat shock protein hsp27 is
correlated with growth and drug resistance in human breast
cancer cell lines. Cancer Res.. 53, 4443 -4448.
PARSELL DA AND LINDQUIST S. (1994). Heat shock proteins and
stress tolerance. In The Biology of Heat Shock Proteins and
Molecular Chaperones RI Morimoto. A Tissiere and C
Georgopoulos (eds) p. 457. Cold Spring Harbour Laboratory
Press: Cold Spring Harbor. NY.
RUIZ VAN- HAPEREN VW AND PETERS GJ. (1994). New targets for
pyrimidine antimetabolites for the treatment of solid tumours. 2:
Deoxycytidine kinase. Pharmacol. World Sci.. 16, 104- I12.
SCHRODER H. LANGER T. HARTL FU AND BUKAU B. (1993).
DnaK. DnaJ and GrpE form a cellular chaperone machinery
capable ofrepairing heat-induced protein damage. EMBO J.. 12,
4137-4144.
SIMON MM. ARAGANE Y. SCHWARZ A. LUGER TA AND SCHWARZ
T. (1994). UVB light induces nuclear factor kappa B (NF kappa B)
activity independently from chromosomal DNA damage in cell-
free cytosolic extracts. J. Invest. Dermatol.. 102, 422-427.
SIMON M.M. REIKERSTORFER A. SCHWARZ A. KRONE C. LUGER
TA. JAATTELA M AND SCHWARZ T. (1995). Heat shock protein
70 overexpression affects the response to ultraviolet light in
murine fibroblasts. Evidence for increased cell viability and
suppression ofcytokine release. J. Clin. Invest.. 95, 926-933.
SINHA BK. (1995). Topoisomerase inhibitors. A review of their
therapeutic potential in cancer. Drugs. 49, 11 - 19.
SKOWYRA D, GEORGOPOULOS C AND ZYLICZ M. (1990). The
E.coli DnaK gene product. the hsp70 homolog. can reactivate
heat inactivated RNA polymerase in an ATP hydrolysis
dependent manner. Cell. 62, 939-944.
SUZUKI K AND WATANABE M. (1994). Modulation of cell growth
and mutation induction by introduction of the expression vector
of human hsp7O gene. Exp. Cell. Res.. 215, 75-81.